Pfizer’s ADCETRIS® Approved by FDA for Relapsed or Refractory Large B-Cell Lymphoma
Pfizer announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) in combination with
Read morePfizer announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS® (brentuximab vedotin) in combination with
Read moreThe Ksander Lab at Boston’s Schepens Eye Research Institute has unveiled valuable insights into the role of subretinal microglia in
Read moreViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced today that
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read moreMillions of individuals worldwide are affected by vision loss caused by retinal degenerative diseases, such as retinitis pigmentosa (RP) and
Read morePresident Donald Trump’s announcement of the $500 billion Stargate initiative marks a transformative moment for the pharmaceutical sector and healthcare
Read moreVariant Bio, a leading genomics-driven drug discovery company, announced today it is entering a new, multi-year research collaboration with pharmaceutical
Read moreWuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today, a new partnership with Candid Therapeutics,
Read moreAstraZeneca’s Truqap (capivasertib) has achieved a significant milestone in the treatment of prostate cancer. Results from the CAPItello-281 Phase III
Read moreInsitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read more